Skip to main content
EJNMMI Research
Fig. 2 | EJNMMI Research

Fig. 2

From: In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

Fig. 2

[177Lu]Lu-PP-F11N and SSTR2 imaging in all patients. [177Lu]Lu-PP-F11N SPECT maximum intensity projection (MIP) of patient 1–8 at 24 h p.i. without (left) and with (middle) Entresto® premedication. MIP of the corresponding SST2R PET/CT for each patient (right). Green arrows: MTC metastases, visible in [177Lu]Lu-PP-F11N scintigraphy. Red arrows: MTC metastases only visible in SST2R PET/CT in a single patient (only two of multiple metastases labelled). Blue arrows: urine contamination. Orange arrowheads: physiological stomach uptake. Furthermore, uptake in kidneys, bowels and urinary bladder is visible in all patients

Back to article page